Author:
Sivakumaran T.,Mileshkin L.,Grant P.,Na L.,DeFazio A.,Friedlander M.,Obermair A.,Webb P.M.,Au-Yeung G.
Funder
AstraZeneca Australia
National Health and Medical Research Council
AstraZeneca Australia.
Subject
Obstetrics and Gynaecology,Oncology
Reference25 articles.
1. Australian Institute of Health and Welfare 2017. Cancer in Australia 2017. Cancer Series No.100. Cat. No. CAN 100. Canberra: AIHW.
2. Primary ovarian cancer chemotherapy: current standards of care;WP;Br. J. Cancer,2003
3. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments;Kyrgiou;J. Natl. Cancer Inst.,2006
4. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III or IV epithelial ovarian cancer;Covens;Gynecol. Oncol.,2002
5. Du Bois A., Quinn M., Thigpen T., Vermorken J., Avall-Lundqvist E., Bookman M., et al. (2005) 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16(Suppl. 8): viii7–viii12.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献